Market Place
Sourcing Support
All News #Library
Biotech
Veru Enrolls 1st Patient In Trial For Enobosarm & Semaglutide
09 Mar 2026 //
GLOBENEWSWIRE
Veru To Present At Oppenheimer Healthcare Life Sciences
19 Feb 2026 //
GLOBENEWSWIRE
Veru Unveils Fy2025 Financials And Clinical Program Advancements
17 Dec 2025 //
GLOBENEWSWIRE
Veru To Present At Sarcopenia Conference And Regulatory Workshop
04 Dec 2025 //
GLOBENEWSWIRE
Veru to Present Two Abstracts at Obesityweek 2025
31 Oct 2025 //
GLOBENEWSWIRE
Veru to Join 2025 BTIG Virtual Biotech Conference
22 Jul 2025 //
GLOBENEWSWIRE
Veru Survey Highlights Muscle Loss Concerns Among GLP-1 Users
15 Jul 2025 //
FIERCE PHARMA
Enobosarm Cuts Weight Regain Post Semaglutide in Ph 2b Trial
24 Jun 2025 //
GLOBENEWSWIRE
Veru`s drug helps older obese patients on Wegovy preserve muscle
28 Jan 2025 //
REUTERS
Veru to Participate in the BTIG Virtual Biotechnology Conference
29 Jul 2024 //
GLOBENEWSWIRE
Veru Enrolls First Patients In Enobosarm-Semaglutide Weight Loss Trial
30 Apr 2024 //
GLOBENEWSWIRE
Veru Reports Fiscal 2023 Third Quarter Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Veru sells combo prostate drug to Blue Water for up to $100M
20 Apr 2023 //
FIERCE PHARMA
Veru Announces Preclinical Results from Expanded Sabizabulin Program
04 Apr 2023 //
GLOBENEWSWIRE
Veru to proceed with late-stage study of COVID pill despite FDA snub
14 Mar 2023 //
REUTERS
FDA rejects Covid-19 drug over uncertainties around small trial
04 Mar 2023 //
ENDPTS
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.